Department of Oncology, Peking University International Hospital, Beijing 102206, China.
Department of Oncology, Chinese PLA General Hospital, Beijing 100853, China.
Exp Biol Med (Maywood). 2020 Apr;245(8):703-710. doi: 10.1177/1535370220914252. Epub 2020 Mar 29.
Non-invasive fibrosis indices, according to regular laboratory and clinical data, could be useful in assessing liver fibrosis in chronic hepatitis patients. However, the role of these biomarkers remains unclear in predicting the outcome of HBV-associated HCC in patients. This study was carried out retrospectively and included a relatively large sample size (n = 405) with a heterogeneous population of HBV infected patients and longer duration of prospective follow-up. Our study suggested that APRI and Fibro-α Scores are inversely correlated with overall survival in HBV-associated HCC patients. Meanwhile, GUCI, King Score, and APRI were highly correlated with cirrhosis status. Also, in subgroups of cirrhosis or non-cirrhosis, Fibro-α Scores could differentiate patients with good prognosis from those with poor outcome. This result would aid clinicians in acquiring preventive and therapeutic methods in patients with high risk.
根据常规实验室和临床数据,非侵入性纤维化指数可用于评估慢性乙型肝炎患者的肝纤维化程度。然而,这些生物标志物在预测乙型肝炎病毒相关 HCC 患者的预后中的作用仍不清楚。本研究为回顾性研究,纳入了相对较大的样本量(n=405),包括异质性的乙型肝炎病毒感染患者和更长时间的前瞻性随访。我们的研究表明,APRI 和 Fibro-α 评分与乙型肝炎病毒相关 HCC 患者的总生存率呈负相关。同时,GUCI、King 评分和 APRI 与肝硬化状态高度相关。此外,在肝硬化或非肝硬化亚组中,Fibro-α 评分可区分预后良好和预后不良的患者。这一结果将有助于临床医生在高危患者中获得预防和治疗方法。